Multiple Reactions to Antihypertensive Agents during Treatment of Malignant Hypertension
Authors: H. MITCHELL PERRY
Journal: Annals of Internal Medicine (1962)

Case Studies1 September 1962Multiple Reactions to Antihypertensive Agents during Treatment of Malignant HypertensionH. MITCHELL PERRY JR., M.D.H. MITCHELL PERRY JR., M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-57-3-441 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDuring the last decade, effective antihypertensive drugs were widely used for the first time. The decreased mortality from severe hypertension (1-4) was expected, but the variety and frequency of associated toxic phenomena were surprising. Each of the first 2 effective drugs was associated with its own unprecedented toxic syndrome. Toxicity from hydralazine simulated rheumatoid arthritis and disseminated lupus erythematosus (5). Hexamethonium produced fatal fibrinous pneumonitis (6). Less catastrophic, but nonetheless impressive neurologic abnormalities, including a characteristic coarse tremor, followed the ingestion of the secondary amine ganglionoplegic agent, mecamylamine (7). The use of milder antihypertensive drugs has evoked less serious and...References1. PERRYSCHROEDER HMHA: A comparison of mortality rates in severe hypertension treated by medical and surgical regimens. Arch. Intern. Med. 102: 418, 1958. CrossrefGoogle Scholar2. DUSTANSCHNECKLOTHCORCORANPAGE HPREACIH: The effectiveness of long-term treatment of malignant hypertension. Circulation 18: 644, 1958. CrossrefMedlineGoogle Scholar3. HARINGTONKINCAID-SMITHMCMICHAEL MPJ: Results of treatment in malignant hypertension. Brit. Med. J. 2: 5158, 1959. CrossrefGoogle Scholar4. HODGEMCQUEENSMIRK JVEGH: Results of hypotensive therapy in arterial hypertension. Brit. Med. J. 1: 1, 1961. CrossrefMedlineGoogle Scholar5. PERRYSCHROEDER HMHA: Delayed toxic manifestations following ingestion of hydralazine. To be published. Google Scholar6. PERRYO'NEALTHOMAS HMRMWA: Pulmonary disease following chronic chemical ganglionic blockade. Amer. J. Med. 22: 37, 1957. CrossrefMedlineGoogle Scholar7. SCHNECKLOTHCORCORANDUSTANPAGE REACHPIH: Mecamylamine in treatment of hypertensive disease. J. A. M. A. 162: 868, 1956. CrossrefMedlineGoogle Scholar8. FRIES ED: Mental depression in hypertensive patients treated for long period with large doses of reserpine. New Engl. J. Med. 251: 1006, 1954. CrossrefMedlineGoogle Scholar9. WEST WO: Perforation and hemorrhage from duodenal ulcer during administration of rauwolfia serpentina: report of 5 cases. Ann. Intern. Med. 48: 1033, 1958. LinkGoogle Scholar10. LARAGHHEINEMANNDEMARTINI JHHOFF: Effect of chlorothiazide on electrolyte transport in man. J. A. M. A. 166: 145, 1958. CrossrefMedlineGoogle Scholar11. ARONOFF A: Acute gouty arthritis precipitated by chlorothiazide. New Engl. J. Med. 262: 767, 1960. CrossrefMedlineGoogle Scholar12. WARSHAW LJ: Acute attacks of gout precipitated by chlorothiazide-induced diuresis. J. A. M. A. 172: 802, 1960. CrossrefMedlineGoogle Scholar13. GOLDNERZAROWITZAKGON MGHS: Hyperglycemia and glycosuria due to thiazide derivative administered in diabetes mellitus. New Engl. J. Med. 262: 403, 1960. CrossrefMedlineGoogle Scholar14. ZELLERGRAFFAGNINOCULLENREITMAN WWPNCFHJ: The use of chlorpromazine and reserpine in the treatment of emotional disorders. J. A. M. A. 160: 179, 1956. CrossrefMedlineGoogle Scholar15. ANTON-STEPHENS D: Preliminary observations of the psychiatric uses of chlorpromazine (Largactil). J. Ment. Sci. 100: 543, 1954. CrossrefMedlineGoogle Scholar16. Registry of Blood Dyscrasias, American Medical Association, Chicago, 1961-62. Google Scholar17. PERRYSCHROEDER HMHA: Neurological manifestations after antihypertensive therapy with mecamylamine. J. A. M. A. 164: 1455, 1957. CrossrefMedlineGoogle Scholar18. DUBOISKATZFREEMANGARBAK ELYJVF: Chronic toxicity studies of hydralazine (Apresoline) in dogs with particular reference to the production of the "hydralazine syndrome." J. Lab. Clin. Med. 50: 119, 1957. MedlineGoogle Scholar19. RALLISONCARLISLELEEVERNIERGOOD MLJWRERLRA: Lupus erythematosus and Stevens-Johnson syndrome. Amer. J. Dis. Child. 101: 725, 1961. CrossrefMedlineGoogle Scholar20. BICKERS J: Hypersensitivity reactions to anti-tuberculous drugs with hepatitis, lupus phenomenon, and myocardial infarction. New Engl. J. Med. 265: 131, 1961. CrossrefGoogle Scholar21. RALLISONO'BRIENGOOD MLJRA: Severe reactions to long acting sulfonamides. Pediatrics 28: 908, 1961. MedlineGoogle Scholar22. HILDEENKROGSAARDVIMTRUP TARB: Fatal pulmonary changes during the medical treatment of malignant hypertension. Lancet 1: 830, 1958. CrossrefMedlineGoogle Scholar23. OLINERSCHWARTZRUBIODAMESHECK HRFW: Interstitial pulmonary fibrosis following busulfan therapy. Amer. J. Med. 31: 134, 1961. CrossrefMedlineGoogle Scholar24. SMYTHEBAROODY CMNB: Hepatic-type "flapping tremor" occurring in patients without hepatic disease. J. A. M. A. 165: 31, 1957. CrossrefMedlineGoogle Scholar25. BIEHLVILTER JPRW: Effects of isoniazid on pyridoxine metabolism. J. A. M. A. 156: 1549, 1954. CrossrefMedlineGoogle Scholar26. KIRKENDALLPAGE WMEB: Polyneuritis occurring during hydralazine therapy. J. A. M. A. 167: 427, 1958. CrossrefMedlineGoogle Scholar27. PERRYSCHROEDERCOMENS HMHAP: Laboratory findings in asymptomatic patients treated with hydralazine. Amer. J. Med. Sci. 244: 44, 1962. CrossrefMedlineGoogle Scholar28. MOSERSYNERMALITZMATTINGLY MJSTW: Acute psychosis as a complication of hydralazine therapy in essential hypertension. J. A. M. A. 152: 1329, 1953. CrossrefMedlineGoogle Scholar29. COHEN BM: Fatal reaction to 1-hydrazinophthalazine (Apresoline). Amer. Heart J. 45: 931, 1953. CrossrefMedlineGoogle Scholar30. BEAVENMURPHY DWEA: Dissecting aneurysm during methonium therapy. Brit. Med. J. 1: 77, 1956. CrossrefMedlineGoogle Scholar31. BARNETT AJ: Letter to the editor. Colitis from ganglion blocking drugs. Lancet 1: 49, 1958. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: St. Louis, MissouriFrom the Hypertension Division, Department of Internal Medicine, Washington University School of Medicine, and Barnes Hospital, St. Louis, Missouri.Supported by the American Heart Association, Ciba Pharmaceutical Products, Inc., and grant No. H 7071 from the United States Public Health Service.This work was begun during the tenure of an Established Investigatorship of the American Heart Association.Requests for reprints should be addressed to H. Mitchell Perry, Jr., M.D., Medical Service of Washington University, Veterans Administration Hospital, 915 North Grand Boulevard, St. Louis 6, Missouri. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByHepatotoxityPossible mechanisms of the hydralazine-related lupus-like syndromeA LUPUS‐LIKE REACTION TO ANTITUBER‐CULOSIS DRUGSAntinuclear Antibodies Following Hydralazine ToxicityStudies on the Control of HypertensionFactors influencing the choice of treatment in essential hypertension 1 September 1962Volume 57, Issue 3Page: 441-450KeywordsDrugsHeartHospital medicineHypertensionMedical servicesMortalityPneumonitisReticulocytesRheumatoid arthritisToxicity Issue Published: 1 September 1962 PDF DownloadLoading ...